Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Double Blind, Randomized, Placebo-Controlled Study of the Safety, Tolerance and Activity of HE3286 When Administered Orally for 12 Weeks to Adult Patients With Type 2 Diabetes Mellitus

NCT00694057 is registered in ClinicalTrials.gov with Harbor Therapeutics as lead sponsor.

NCT NCT00694057
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00694057 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Double Blind, Randomized, Placebo-Controlled Study of the Safety, Tolerance and Activity of HE3286 When Administered Orally for 12 Weeks to Adult Patients With Type 2 Diabetes Mellitus
Lead sponsor
Harbor Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2008
Completion date
January 31, 2010
Enrollment
164 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes mellitus